MBX Biosciences Common StockNASDAQ: MBX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

14 January 2000

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$489.70 M
-37%vs. 3y high
66%vs. sector
-vs. 3y high
-vs. sector
-37%vs. 3y high
54%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Wed, 20 Nov 2024 14:30:00 GMT
$16.24+$0.30(+1.88%)

Dividend

No data over the past 3 years
$0.00-$18.14 M

Analysts recommendations

Institutional Ownership

Included in screeners

No data

MBX Latest News

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
globenewswire.com18 November 2024 Sentiment: POSITIVE

CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the completion of the last subject's last visit in its Phase 1 single and multiple ascending dose trial of MBX 1416, the Company's long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist in development for the treatment of post-bariatric hypoglycemia (PBH).

MBX Biosciences to Participate in Upcoming November Investor Conferences
globenewswire.com28 October 2024 Sentiment: POSITIVE

CARMEL, Ind., Oct. 28, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its management team will participate in the following upcoming investor conferences:

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting
globenewswire.com30 September 2024 Sentiment: POSITIVE

CARMEL, Ind., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that both the rationale and design of the Phase 2 Avail™ trial of MBX 2109, the Company's potential long-acting parathyroid hormone (PTH) peptide prodrug, in adults with hypoparathyroidism (HP) were featured in a poster presentation at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting held in Toronto, ON, Canada September 27-30, 2024.

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
globenewswire.com16 September 2024 Sentiment: POSITIVE

CARMEL, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the closing of its previously announced upsized initial public offering of 11,730,000 of its common stock at a price to the public of $16.00 per share, which includes 1,530,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The aggregate gross proceeds to MBX Biosciences from the offering were approximately $187.7 million, before deducting underwriting discounts and commissions and offering expenses.

What type of business is MBX Biosciences Common Stock?

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

What sector is MBX Biosciences Common Stock in?

MBX Biosciences Common Stock is in the Healthcare sector

What industry is MBX Biosciences Common Stock in?

MBX Biosciences Common Stock is in the Biotechnology industry

What country is MBX Biosciences Common Stock from?

MBX Biosciences Common Stock is headquartered in United States

When did MBX Biosciences Common Stock go public?

MBX Biosciences Common Stock initial public offering (IPO) was on 14 January 2000

What is MBX Biosciences Common Stock website?

https://mbxbio.com

Is MBX Biosciences Common Stock in the S&P 500?

No, MBX Biosciences Common Stock is not included in the S&P 500 index

Is MBX Biosciences Common Stock in the NASDAQ 100?

No, MBX Biosciences Common Stock is not included in the NASDAQ 100 index

Is MBX Biosciences Common Stock in the Dow Jones?

No, MBX Biosciences Common Stock is not included in the Dow Jones index

When was MBX Biosciences Common Stock the previous earnings report?

No data

When does MBX Biosciences Common Stock earnings report?

The next expected earnings date for MBX Biosciences Common Stock is 28 February 2025